From the Department of Pharmacy, University of Rochester Medical Center, Rochester, NY (RFS, KMM, JMC, SR, NMA); Department of Emergency Medicine, University of Rochester Medical Center, Rochester NY (RFS, TJW, JM, NMA); Department of Surgical Critical Care, Medstar Washington Hospital Center, Washington, DC (BM); and Department of Critical Care Medicine, Ballad Health - Johnson City Medical Center, Johnson City, TN (TC).
J Addict Med. 2023;17(6):685-690. doi: 10.1097/ADM.0000000000001214. Epub 2023 Aug 18.
Buprenorphine can be challenging to initiate in hospitalized patients with opioid dependence because of difficulty tolerating an opioid-free period for buprenorphine induction. The objective of this study was to evaluate efficacy and safety of low-dose initiation of buprenorphine in hospitalized patients receiving full agonist opioids.
This is a retrospective observational study between January 1, 2019, and December 31, 2020, at an academic tertiary care center and affiliated community hospital. Participants included adult patients at least 18 years old receiving scheduled full agonist opioids who were given sublingual buprenorphine 0.5 mg or less with the intent of increasing to at least 4 mg daily. The primary endpoint was the proportion of patients reaching a target dose of at least 4 mg total per day. The secondary endpoints included the incidence of precipitated opioid withdrawal based on documentation of symptoms and change in morphine milligram equivalents before and after low-dose buprenorphine initiation.
A total of 76 low-dose initiation attempts were performed in 71 predominantly male (68%) patients (some patients had multiple attempts). Most patients received low-dose initiation because of history of opioid use disorder (83%). Low-dose initiation was completed in 54 of 71 patients (76%) after 76 attempts. Precipitated withdrawal was identified in 2 patients (2.8%). Median morphine milligram equivalents excluding buprenorphine 24 hours before low-dose initiation was 1000 mg (interquartile range, 303.5-1720.5 mg) compared with 37.5 mg (interquartile range, 0-254 mg) after reaching target dose ( P < 0.001).
Buprenorphine was safely initiated using low-dose initiation in hospitalized patients. This was associated with significant reduction in full agonist opioids.
由于难以耐受阿片类药物戒断期,因此,在住院的阿片类药物依赖患者中开始使用丁丙诺啡可能具有挑战性。本研究的目的是评估在接受完全激动剂阿片类药物的住院患者中,使用低剂量丁丙诺啡起始治疗的疗效和安全性。
这是一项在学术性三级保健中心及其附属社区医院进行的回顾性观察性研究,时间为 2019 年 1 月 1 日至 2020 年 12 月 31 日。参与者包括至少 18 岁、正在接受计划内使用完全激动剂阿片类药物的成年患者,这些患者给予舌下丁丙诺啡 0.5mg 或更少剂量,目的是每天增加至至少 4mg。主要终点是达到每天至少 4mg 总剂量的患者比例。次要终点包括根据症状记录和开始低剂量丁丙诺啡前后吗啡毫克当量的变化来确定是否出现阿片类药物撤药反应。
71 名主要为男性(68%)患者(部分患者进行了多次尝试)共进行了 76 次低剂量起始尝试。大多数患者因阿片类药物使用障碍史而接受低剂量起始治疗(83%)。在 76 次尝试后,54 名患者(76%)完成了低剂量起始治疗。2 名患者(2.8%)出现撤药反应。与达到目标剂量后相比,低剂量起始前 24 小时的吗啡毫克当量中位数(四分位距,303.5-1720.5mg)为 1000mg(四分位距,303.5-1720.5mg),为 37.5mg(四分位距,0-254mg)(P<0.001)。
在住院患者中使用低剂量起始丁丙诺啡是安全的。这与完全激动剂阿片类药物的用量显著减少有关。